Observational studyWorld journal of gastroenterology2015
Prolonged overall survival in gastric cancer patients after adoptive immunotherapy.
Observational study in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- A Comprehensive Review on Novel Therapies for Gastrointestinal Cancers using Translational Platforms.Current pharmaceutical design · 2025Review
- Visual analysis of global research on immunotherapy for gastric cancer: A literature mining from 2012 to 2022.Human vaccines & immunotherapeutics · 2023Article
- Novel insight into the role of immunotherapy in gastrointestinal cancer (Review).Molecular and clinical oncology · 2022Review
- BGN May be a Potential Prognostic Biomarker and Associated With Immune Cell Enrichment of Gastric Cancer.Frontiers in genetics · 2022Article
- Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and -γ.Frontiers in immunology · 2021Review
- Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction?Frontiers in oncology · 2020Review
- Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer.World journal of gastroenterology · 2018Review
- Disappearance of bone metastases in chemotherapy-resistant gastric cancer treated with antigen peptide-pulsed dendritic cell-activated cytotoxic T lymphocyte immunotherapy: A case report.Oncology letters · 2018Article
- Immunotherapy for Gastric Cancer: Time for a Personalized Approach?International journal of molecular sciences · 2018Review
- Cellular immunity augmentation in mainstream oncologic therapy.Cancer biology & medicine · 2017Article
- Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development.BioMed research international · 2017Review
- Optimizing Radiotherapy with Immunotherapeutic Approaches.Advances in experimental medicine and biology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo assess the efficacy of immunotherapy with expanded activated autologous lymphocytes (EAALs) in gastric cancer.
methodsAn observational study was designed to retrospectively analyze the clinical data of 84 gastric cancer patients, of whom 42 were treated by EAAL immunotherapy plus conventional treatment and another 42 only received conventional treatment (control group). EAALs were obtained by proliferation of peripheral blood mononuclear cells from patients followed by phenotype determination. Clinical data including age, gender, clinical stage, chemotherapeutic regimens, hospitalization, surgical, radiotherapy, and survival data were collected along with EAAL therapy details and side effects. Patients were followed and the relationship between treatment and overall survival (OS) data obtained for the immunotherapy and control groups were compared retrospectively. The safety of EAAL immunotherapy was also evaluated.
resultsAfter in vitro culture and proliferation, the percentages of CD3+, CD3+CD8+, CD8+CD27+, CD8+CD28+, and CD3+CD16+/CD56+ cells increased remarkably (P < 0.05), while the percentages of CD3+CD4+, CD4+CD25+, and CD3-CD16+/CD56+ (natural killer cells) were overtly decreased (P < 0.05); no significant change was observed in CD4+CD25+CD127- cells (P = 0.448). Interestingly, OS in the immunotherapy group was significantly higher than that in the control group, with 27.0 and 13.9 mo obtained for the two groups, respectively (P = 0.028, HR = 0.573, 95%CI: 0.347-0.945). These findings indicated a 42.7% decrease in the risk of death. In addition, we found that clinical stage and application of EAAL immunotherapy were independent prognostic factors for gastric cancer patients. Indeed, the OS in stage IIIc and IV patients that had received surgery was prolonged after EAAL immunotherapy (P < 0.05). Importantly, in vitro induction and proliferation of EAAL were easy and biologically safe.
conclusionOverall, EAAL adoptive immunotherapy might prolong the OS in gastric cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.